贲门癌组织中程序性细胞死亡受体-1、程序性细胞死亡配体-1的表达水平及价值  

Clinical significance of PD-1 and PD-L1 in cardiac carcinoma tissues

作　　者：朱卫伟 周福有 许海生 ZHU Wei-wei;ZHOU Fu-you;XU Hai-sheng(Anyang Oncology Hospital,The Fourth Affiliated Hospital of Henan University of Science and Technology,Anyang Henan 455000,China)

机构地区：[1]安阳市肿瘤医院河南科技大学第四附属医院,河南安阳455000

出　　处：《中国卫生工程学》2022年第2期223-225,228,共4页Chinese Journal of Public Health Engineering

基　　金：河南省医学科技攻关计划项目(LHGJ20191283)。

摘　　要：目的 探讨贲门癌组织中程序性细胞死亡受体-1(PD-1)和程序性细胞死亡配体-1(PD-L1)的表达水平及价值。方法 选取本院2019年1月至2020年1月78例经手术治疗的贲门癌患者,术后取癌组织及癌旁组织,采用免疫组织化学法检测PD-1、PD-L1表达,比较癌组织及癌旁组织中上述指标表达情况并分析其与贲门癌患者临床病理特征的关系。结果 贲门癌患者癌组织PD-1、PD-L1阳性表达率分别为53.85%、61.54%,高于对照组的11.54%、15.38%,差异均有统计学意义(均P<0.05)。贲门癌患者癌组织中PD-1、PD-L1阳性表达率与临床分期、肿瘤直径、分化程度、淋巴结转移、浸润深度有关(均P<0.05),与年龄、性别无关(均P>0.05)。结论 贲门癌患者癌组织中PD-1、PD-L1呈高表达,不同临床病理特征患者上述指标水平存在显著差异,两者可为评估贲门癌病情发展提供参考。Objective This paper aims to explore the clinical significance of programmed death receptor-1(PD-1) and programmed death ligand-1(PD-L1) in cardiac carcinoma tissues. Methods A total of 78 patients with cardiac carcinoma undergoing surgical treatment in the hospital from January 2019 to January 2020 were enrolled. The cancerous tissues and para-cancerous tissues were collected after surgery. The expressions of PD-1 and PD-L1 were detected by immunohistochemistry. The expressions of PD-1 and PD-L1 in cancerous tissues and para-cancerous tissues were compared. The relationship between the two indexes and clinicopathological characteristics of cardiac carcinoma patients was analyzed. Results The positive expression rates of PD-1 and PD-L1 in cancer tissues of cardiac carcinoma patients were 53.85% and 61.54%, higher than those in control group(11.54%, 15.38%)(P<0.05). The positive expression rates of PD-1 and PD-L1 were related to clinical staging, tumor diameter, differentiation degree, lymph node metastasis and invasion depth(P<0.05), but not related to age or gender of cardiac carcinoma patients(P>0.05).Conclusion PD-1 and PD-L1 in cancer tissues are highly expressed in cardiac carcinoma patients. There are significant differences in the expressions of PD-1 and PD-L1 among patients with different clinicopathological characteristics. The two indexes can be applied as the evaluation indexes for the development of cardiac carcinoma.

关 键 词：贲门癌 程序性细胞死亡受体-1 程序性细胞死亡配体-1 临床分期 病理特征 

分 类 号：R573[医药卫生—消化系统]